IN2014MN02104A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02104A
IN2014MN02104A IN2104MUN2014A IN2014MN02104A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A IN 2104MUN2014 A IN2104MUN2014 A IN 2104MUN2014A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A
Authority
IN
India
Prior art keywords
hydroxyacrylamide
dihydro
oxo
ethyl
compound
Prior art date
Application number
Inventor
Ji Wang Chern
Chao Wu Yu
Pei Teh Chang
Original Assignee
Annji Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharm Co Ltd filed Critical Annji Pharm Co Ltd
Publication of IN2014MN02104A publication Critical patent/IN2014MN02104A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In an embodiment of the invention the compound is (2E) 3 (2 ethyl 6 fluoro 3 4 dihydro 4 oxo 3 phenethylquina20lin 7 yl) N hydroxyacrylamide or a salt thereof. In another embodiment of the invention the compound is (2E) 3 (2 ethyl 7 f1uoro 3 4 dihydro 4 oxo 3 phenethylquinazolin 6 yl) N hydroxyacrylamide (2E) 3 (7 chloro 2 ethyl 3 4 dihydro 4 oxo 3 phenethylquinazolin 6 yl) N hydroxyacrylamide or a salt thereof. In another aspect the invention relates to a composition comprising a therapeutically effective amount of a compound as aforementioned or a pharmaceutically acceptable salt a solvate or hydrate a prodrug or a metabolite thereof and a pharmaceutically acceptable carrier or vehicle.
IN2104MUN2014 2012-04-10 2013-04-02 IN2014MN02104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261622127P 2012-04-10 2012-04-10
PCT/US2013/035004 WO2013154870A1 (en) 2012-04-10 2013-04-02 Histone deacetylases (hdacs) inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02104A true IN2014MN02104A (en) 2015-09-04

Family

ID=49292802

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2104MUN2014 IN2014MN02104A (en) 2012-04-10 2013-04-02

Country Status (13)

Country Link
US (2) US9387209B2 (en)
EP (1) EP2836484B1 (en)
JP (1) JP6258918B2 (en)
KR (1) KR101781922B1 (en)
CN (1) CN104364237B (en)
AU (1) AU2013246278B2 (en)
BR (1) BR112014025122B1 (en)
ES (1) ES2630062T3 (en)
IL (1) IL235053A (en)
IN (1) IN2014MN02104A (en)
RU (1) RU2629947C2 (en)
TW (1) TWI481597B (en)
WO (1) WO2013154870A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889656B (en) 2011-09-12 2017-03-15 应用材料公司 There is the carrier header of complex plastic part
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (en) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017508798A (en) * 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC)
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
WO2015153516A1 (en) * 2014-04-04 2015-10-08 University Of Florida Research Foundation Hdac inhibitor compounds and methods of treatment
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2915827T3 (en) * 2017-05-16 2022-06-27 Annji Pharm Co Ltd Histone acetylase inhibitors (HDACs)
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
KR20210116830A (en) * 2020-03-17 2021-09-28 충북대학교 산학협력단 Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides and its use
CN111517977B (en) * 2020-05-28 2023-05-23 爱斯特（成都）生物制药股份有限公司 Method for synthesizing 2, 4-difluoro-3-trimethyl acetamido benzoic acid
MX2022015532A (en) 2020-06-08 2023-04-04 Annji Pharm Co Ltd Quinazoline derivatives useful as selective hdac6 inhibitors.
WO2023159155A1 (en) * 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH464935A (en) * 1965-05-12 1968-11-15 Sumitomo Chemical Co Process for the production of new quinazolinone derivatives
FR6001M (en) * 1966-12-02 1968-04-29
ZA705270B (en) * 1969-08-02 1971-04-28 Sumitomo Chemical Co Novel quinazolinone derivatives and a process for production thereof
US4054658A (en) * 1974-02-06 1977-10-18 William H. Rorer, Inc. Therapeutic compositions containing methaqualone
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JP3488890B2 (en) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 3-N-substituted quinazolinone derivatives, process for producing the same, and herbicides containing the compounds
AU2001248701A1 (en) * 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
EP1524262A1 (en) * 2000-03-24 2005-04-20 Methylgene, Inc. Inhibitors of histone deacetylase
MXPA05004328A (en) * 2002-11-04 2005-08-02 Nps Pharma Inc Quinazolinone compounds as calcilytics.
ITMI20041869A1 (en) 2004-10-01 2005-01-01 Dac Srl NEW INHIBITORS OF DEACETYLASE HISTONS
CN101263125A (en) * 2005-07-15 2008-09-10 先灵公司 Quinazoline derivatives useful in cancer treatment
AU2006298881A1 (en) 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0624187D0 (en) 2006-12-04 2007-01-10 Jackson William P HDAC inhibitors
WO2008087514A2 (en) 2007-01-17 2008-07-24 Orchid Research Laboratories Limited Hdac inhibitors
JP2010536876A (en) 2007-08-21 2010-12-02 アークル インコーポレイテッド HDAC inhibitor
AU2008307541B2 (en) 2007-10-01 2015-02-12 Lixte Biotechnology, Inc. HDAC inhibitors
EP2456757B1 (en) 2009-07-22 2019-05-01 The Board of Trustees of the University of Illionis Hdac inhibitors and therapeutic methods using the same

Also Published As

Publication number Publication date
AU2013246278A1 (en) 2014-11-13
US9387209B2 (en) 2016-07-12
TWI481597B (en) 2015-04-21
US20150196563A1 (en) 2015-07-16
CN104364237B (en) 2016-08-24
WO2013154870A1 (en) 2013-10-17
BR112014025122A2 (en) 2021-07-06
RU2629947C2 (en) 2017-09-05
TW201345898A (en) 2013-11-16
KR101781922B1 (en) 2017-09-26
EP2836484A1 (en) 2015-02-18
EP2836484A4 (en) 2015-09-02
JP2015512939A (en) 2015-04-30
KR20150000901A (en) 2015-01-05
US20130267542A1 (en) 2013-10-10
CN104364237A (en) 2015-02-18
AU2013246278B2 (en) 2016-11-03
ES2630062T3 (en) 2017-08-17
JP6258918B2 (en) 2018-01-10
IL235053A (en) 2017-09-28
RU2014144142A (en) 2016-06-10
EP2836484B1 (en) 2017-06-14
US9155739B2 (en) 2015-10-13
BR112014025122B1 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
IN2014MN02104A (en)
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
DOP2016000124A (en) PIRROLO [2,3-D] PYRIMIDINYL, PIRROLO [2,3-B] PYRAZINYL AND PIRROLO [2,3-D] PIRIDINYL ACRYLIC
MX2017013801A (en) Methods of treating cancer.
CR20140413A (en) SERINA / TREONINA CINASA INHIBITORS
MD20160017A2 (en) Polymorph of SYK inhibitors
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
MX2013011589A (en) Methods and compositions for treating parkinson's disease.
MX2016017030A (en) Mnk inhibitors and methods related thereto.
AU2012214029A8 (en) Rorgammat inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MD4684B1 (en) Imidazopyrazine-based formulations as SYK inhibitors
MX2013011591A (en) Methods and compositions for treating neurodegenerative diseases.
MX2016008624A (en) Serine/threonine kinase inhibitors.
MX2015003728A (en) Combination of regorafenib and acetylsalicylic acid for treating cancer.
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
IN2015DN01119A (en)
MX345780B (en) Tricyclic gyrase inhibitors.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
IN2012DN02556A (en)
BR112012031340A2 (en) cyanoquinoline derivatives
MX2013002620A (en) Novel n-hydroxy-benzamides for the treatment of cancer.
PH12014502747A1 (en) Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
WO2014163622A8 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents